Home / Biotech/Pharma / MediWound to Ring the NASDAQ Stock Market Closing Bell in Recognition of Burn Awareness Week
Photo Credit: US Navy, {{PD-user|BotMultichillT}}, Navy ID 100528-N-9589S-001, altered

MediWound to Ring the NASDAQ Stock Market Closing Bell in Recognition of Burn Awareness Week מדיוונד יצלצל פעמון הסגירה בבורסת הנאסד"ק כחלק משבוע של מודעות לצריבה

MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced that Gal Cohen, MediWound’s Chief Executive Officer, will ring the NASDAQ Stock Market Closing Bell today (February 5, 2015) in recognition of the American Burn Association’s Burn Awareness Week taking place from February 1-7, 2015.

“We are delighted to close the NASDAQ stock market in recognition of Burn Awareness Week, as MediWound has devoted its efforts to advancing burn care for more than a decade,” noted Mr. Cohen. “The NASDAQ has provided MediWound with the platform to raise capital to support our efforts to bring an innovative, minimally-invasive modality to burn care. Our lead product, NexoBrid®, enables burn specialists to use a four-hour, non-surgical, bedside application to swiftly debride burns while still protecting the patients’ unharmed tissue. NexoBrid is approved and marketed throughout Europe. We are committed to advancing our efforts to make NexoBrid available to U.S. and pediatric burn specialists through our clinical phase 3 trials and to extending NexoBrid’s reach to additional emerging international markets through agreements with local distribution partners.”


Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio


Thursday, February 5, 2015 – 3:45 p.m. to 4:00 p.m. ET


A webcast of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx.    


About MediWound Ltd.

Based in Yavne, MediWound Ltd. is a biotechnology niche specialty company focused on developing, manufacturing and globally commercializing innovative products that address unmet needs in the fields of severe burn and chronic wound management. MediWound’s first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated with statistical significance its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissues.



About bio972